Absci Corporation
NMS: ABSILive Quote
📈 ZcoreAI Score
Our AI model analyzes Absci Corporation's price action across multiple timeframes using regression channels and statistical scoring.
Get ABSI Z-Score →About Absci Corporation
Healthcare
Biotechnology
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
📊 Fundamental Analysis
Absci Corporation demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -2.3% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -62.5%, which indicates that capital utilization is currently under pressure.
At a current price of $2.98, ABSI currently sits at the 25th percentile of its 52-week range (Range: $2.24 - $5.23).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$456.00M
Trailing P/E
--
Forward P/E
-4.75
Beta (5Y)
2.01
52W High
$5.23
52W Low
$2.24
Avg Volume
3.57M
Day High
Day Low